




The relative strengths and weaknesses of Keros Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Keros Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 130% points. The greatest weakness of Keros Therapeutics Inc is the variable Research and Development, reducing the Economic Capital Ratio by 6.0% points.

The company's Economic Capital Ratio, given in the ranking table, is 405%, being 130% points above the market average of 275%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	251,440	Assets	255,251
Cost of Goods Sold	0	Liabilities	12,077
Intangible Assets	0	Expenses	78,484
Liabilities, Current	11,846	Revenues	20,100
Liabilities, Non-Current	231	Stockholders Equity	243,174
Other Assets	2,476	Net Income	-58,744
Other Compr. Net Income	0	Comprehensive Net Income	-58,744
Other Expenses	2,011	BaseVar	183,136
Other Liabilities	0	ECR before LimitedLiability	353%
Other Net Income	-360	Economic Capital Ratio	405%
Other Revenues	20,100		
Property and Equipment	1,335		
Research and Development	55,143		
Selling, General and Administrative Expense	21,330		